Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study
Ton Fang, Ahmad Al Khleifat, Jacques-Henri Meurgey, et al.
The Lancet Neurology (2018) Vol. 17, Iss. 5, pp. 416-422
Open Access | Times Cited: 226

Showing 26-50 of 226 citing articles:

Pathologically mislocalised TDP-43 in upper motor neurons causes a die-forward spread of ALS-like pathogenic changes throughout the mouse corticomotor system
Laura A. Reale, Marcus S. Dyer, Sharn Perry, et al.
Progress in Neurobiology (2023) Vol. 226, pp. 102449-102449
Closed Access | Times Cited: 23
The role of CD56bright NK cells in neurodegenerative disorders
Carla Rodriguez-Mogeda, Chaja M. J. van Ansenwoude, Lennart van der Molen, et al.
Journal of Neuroinflammation (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 13
Protein aggregation and therapeutic strategies in SOD1- and TDP-43- linked ALS
Maria Tsekrekou, Μαρία Γιαννάκου, Katerina Papanikolopoulou, et al.
Frontiers in Molecular Biosciences (2024) Vol. 11
Open Access | Times Cited: 13
Update on recent advances in amyotrophic lateral sclerosis
Nilo Riva, Teuta Domi, Laura Pozzi, et al.
Journal of Neurology (2024) Vol. 271, Iss. 7, pp. 4693-4723
Open Access | Times Cited: 11
Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial
Albert C. Ludolph, Joachim Schuster, Johannes Dorst, et al.
The Lancet Neurology (2018) Vol. 17, Iss. 8, pp. 681-688
Open Access | Times Cited: 71
Cortical hyperexcitability evolves with disease progression in ALS
Parvathi Menon, Mana Higashihara, Mehdi van den Bos, et al.
Annals of Clinical and Translational Neurology (2020) Vol. 7, Iss. 5, pp. 733-741
Open Access | Times Cited: 64
Riluzole for the Treatment of Amyotrophic Lateral Sclerosis
Yuji Saitoh, Yuji Takahashi
Neurodegenerative Disease Management (2020) Vol. 10, Iss. 6, pp. 343-355
Closed Access | Times Cited: 50
An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials
Ruben P.A. van Eijk, Adriaan D. de Jongh, Stavros Nikolakopoulos, et al.
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (2021) Vol. 22, Iss. 3-4, pp. 300-307
Open Access | Times Cited: 48
The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial
Eleonora Dalla Bella, Enrica Bersano, Giovanni Antonini, et al.
Brain (2021) Vol. 144, Iss. 9, pp. 2635-2647
Open Access | Times Cited: 48
A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?
Xiaojiao Xu, Dingding Shen, Yining Gao, et al.
Translational Neurodegeneration (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 45
Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double-blind, placebo-controlled trial
Giulia Coarelli, Anna Heinzmann, Claire Ewenczyk, et al.
The Lancet Neurology (2022) Vol. 21, Iss. 3, pp. 225-233
Open Access | Times Cited: 37
Preclinical evaluation of WVE-004, an investigational stereopure oligonucleotide for the treatment of C9orf72-associated ALS or FTD
Yuanjing Liu, Amy Andreucci, Naoki Iwamoto, et al.
Molecular Therapy — Nucleic Acids (2022) Vol. 28, pp. 558-570
Open Access | Times Cited: 36
Oxidative Stress in Amyotrophic Lateral Sclerosis: Synergy of Genetic and Environmental Factors
Anca Moțățăianu, Georgiana Șerban, Laura Bărcuțean, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 9339-9339
Open Access | Times Cited: 36
Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis
Marie Dreger, Robert Steinbach, Markus Otto, et al.
Journal of Neurology Neurosurgery & Psychiatry (2022) Vol. 93, Iss. 4, pp. 422-435
Open Access | Times Cited: 34
Drug discovery and amyotrophic lateral sclerosis: Emerging challenges and therapeutic opportunities
Pedro Soares, Catia Silva, Daniel Chavarria, et al.
Ageing Research Reviews (2022) Vol. 83, pp. 101790-101790
Open Access | Times Cited: 28
Cortical hyperexcitability in amyotrophic lateral sclerosis: from pathogenesis to diagnosis
Hannah C. Timmins, Steve Vucic, Matthew C. Kiernan
Current Opinion in Neurology (2023) Vol. 36, Iss. 4, pp. 353-359
Closed Access | Times Cited: 17
Mitochondrial Dyshomeostasis as an Early Hallmark and a Therapeutic Target in Amyotrophic Lateral Sclerosis
Natalia V. Belosludtseva, Lyudmila A. Matveeva, Konstantin N. Belosludtsev
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 23, pp. 16833-16833
Open Access | Times Cited: 17
Transcranial static magnetic stimulation for amyotrophic lateral sclerosis: a bicentric, randomised, double-blind placebo-controlled phase 2 trial
Vincenzo Di Lazzaro, Federico Ranieri, Alberto Doretti, et al.
The Lancet Regional Health - Europe (2024) Vol. 45, pp. 101019-101019
Open Access | Times Cited: 6
Objectively Monitoring Amyotrophic Lateral Sclerosis Patient Symptoms During Clinical Trials With Sensors: Observational Study
Luis Garcia‐Gancedo, Madeline L Kelly, Arseniy Lavrov, et al.
JMIR mhealth and uhealth (2019) Vol. 7, Iss. 12, pp. e13433-e13433
Open Access | Times Cited: 44
Novel Selenium-based compounds with therapeutic potential for SOD1-linked amyotrophic lateral sclerosis
Kangsa Amporndanai, Michael S. Rogers, Seiji Watanabe, et al.
EBioMedicine (2020) Vol. 59, pp. 102980-102980
Open Access | Times Cited: 44
Tumor Necrosis Factor Alpha in Amyotrophic Lateral Sclerosis: Friend or Foe?
Giulia Guidotti, Chiara Scarlata, Liliana Brambilla, et al.
Cells (2021) Vol. 10, Iss. 3, pp. 518-518
Open Access | Times Cited: 35
Oxidative Stress as a Therapeutic Target in Amyotrophic Lateral Sclerosis: Opportunities and Limitations
Hee Ra Park, Eun Jin Yang
Diagnostics (2021) Vol. 11, Iss. 9, pp. 1546-1546
Open Access | Times Cited: 34
Emerging technologies for management of patients with amyotrophic lateral sclerosis: from telehealth to assistive robotics and neural interfaces
Raffaele Pugliese, Riccardo Della Sala, Stefano Regondi, et al.
Journal of Neurology (2022) Vol. 269, Iss. 6, pp. 2910-2921
Open Access | Times Cited: 23
Therapeutic targeting ofALSpathways: Refocusing an incomplete picture
Nicholas J. Maragakis, Mamede de Carvalho, Michael D. Weiss
Annals of Clinical and Translational Neurology (2023) Vol. 10, Iss. 11, pp. 1948-1971
Open Access | Times Cited: 15
Current potential therapeutics of amyotrophic lateral sclerosis
Lijun Lu, Youqing Deng, Renshi Xu
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 5

Scroll to top